To explore the possible mechanism by which calpain inhibition promotes hepatic steatosis, we evaluated the protein abundance of PPARγ, which is cleaved by CAPN1 in cell-free systems [20] and promotes de novo lipogenesis in MASLD [21]. Here, PPARG is linked to metabolic dysfunction-associated steatotic liver disease.